By HiMiyer.com — March 23, 2026
.JPG)
What Is NMN?
Nicotinamide mononucleotide (NMN) is a compound the body uses to produce NAD+ (nicotinamide adenine dinucleotide), a molecule essential for cellular energy production, DNA repair, and metabolic function. NAD+ levels naturally decline with age, and NMN supplements have attracted significant consumer interest as a potential way to restore those levels. Human clinical trials have confirmed NMN reliably raises blood NAD+ levels, with early signals for improved physical function and insulin sensitivity, though longevity claims remain unproven in humans.
The 2022 Ban
In November 2022, the FDA declared that NMN could not be marketed as a dietary supplement, citing the drug preclusion clause of the Food, Drug, and Cosmetic Act. The agency determined that because a company called MetroBiotech had filed an Investigational New Drug (IND) application for NMN before it was widely marketed as a supplement, the ingredient was legally classified as a pharmaceutical candidate rather than a dietary ingredient. Amazon promptly delisted NMN products, and the supplement industry scrambled to respond.
The 2025 Reversal
Following a formal citizen petition by the Natural Products Association and the Alliance for Natural Health USA, and ultimately a 2024 lawsuit by the NPA against the FDA, the agency reversed course on September 29, 2025. The FDA concluded that NMN had in fact been marketed as a dietary supplement in the United States as early as 2017 — before MetroBiotech's drug investigation became public — satisfying the "race to market" provision under DSHEA. In December 2025, the FDA sent formal letters to manufacturers SyncoZymes and Inner Mongolia Kingdomway reinstating their New Dietary Ingredient (NDI) notifications.
What It Means for Consumers in 2026
NMN products are now legally available across U.S. retail and e-commerce channels. The market has expanded rapidly since the reversal; prices range from roughly $20 to over $150 for comparable doses, making quality verification critical. Consumers should look for products that provide third-party testing documentation, clearly disclose the NMN dose per serving, and are manufactured under current Good Manufacturing Practices (cGMP).
Remaining Questions
The FDA's reversal resolved the NMN question specifically but left the broader drug preclusion clause intact. The Council for Responsible Nutrition noted the ruling fails to address the structural framework that caused the NMN dispute in the first place, meaning future ingredients could face the same regulatory uncertainty. The NPA has indicated it will pursue a legislative fix to the drug preclusion clause to prevent recurrence.
